ninety-four evaluable patients with metastatic soft tissue and bone sarcomas entered into a prospective randomized trial ( seg 78sar327 ) to determine whether amphotericin b ( amb ) , a membrane-permeabilizing and immunopotentiating agent , could increase either the response rates or the survival of patients treated with a three-drug combination chemotherapy regimen consisting of adriamycin , cyclophosphamide , and methotrexate ( acm ) .
C0029463
bone sarcomas
C0025677
methotrexate